AC
Therapeutic Areas
Aktis Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| AKY-1189 | Nectin-4 expressing solid tumors (Urothelial Carcinoma, Breast Cancer, NSCLC, Colorectal Cancer, Cervical Cancer) | Phase 1b |
| AKY-2519 | B7-H3 (CD276) expressing solid tumors (Prostate, Lung, and other solid tumors) | IND-Enabling |
| Multiple Programs | Undisclosed solid tumors | Discovery |
Leadership Team at Aktis Oncology
MR
Matthew Roden, PhD
President, Chief Executive Officer
TB
Tyler Benedum, PhD
Chief Technical Officer
PL
Paul L. Feldman, PhD
Chief Scientific Officer
KK
Kyle Kuvalanka
Chief Financial Officer
SR
Shulamit Ron-Bigger, PhD
Chief Operating Officer
TF
Todd Foley
Co-founder and Chairman of the Board
KH
Ken Herrmann, MD
Independent Director, Chair of Scientific Advisory Board